Pharmaceutical

Genprex’s Reqorsa gene therapy picks up orphan drug designation from FDA for SCLC

The latest tag adds to three fast track designations for Reqorsa, with the company initiating a Phase I/II trial in Q4 2023.

Aug 12, 2023 - 20:00
Genprex’s Reqorsa gene therapy picks up orphan drug designation from FDA for SCLC
The latest tag adds to three fast track designations for Reqorsa, with the company initiating a Phase I/II trial in Q4 2023.
Read the original article

Tags:

Previous Article

STAT+: Where are patients getting their prescriptions for GLP-1 drugs like Wegov...

Next Article

TriSalus merges with MedTech Acquisition to bolster cash reserves

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Pharmalittle: More than 9 in 10 pharmacy techs report drug shortages; Yale and VA strike deal over ketamine patent royalties

STAT+: Pharmalittle: More than 9 in 10 pharmacy techs r...

Sep 22, 2023

STAT+: Flagship Pioneering launches Quotient, a new biotech, in two countries

STAT+: Flagship Pioneering launches Quotient, a new bio...

Nov 21, 2023

STAT+: Pharmalittle: FDA approves over-the-counter Narcan; J&J exits the race for the first RSV vaccine

STAT+: Pharmalittle: FDA approves over-the-counter Narc...

Mar 30, 2023